Patent intelligence · US
US 10792370
Antibody-drug conjugate
Antibody-drug conjugate
Patent details — US 10792370
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 6, 2020
- Expiration
- Oct 1, 2040
- Applicant
- SHANGHAI MIRACOGEN INC.
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K38/1808, A61K39/001104
Quick answer
US 10792370 (Antibody-drug conjugate) is held by SHANGHAI MIRACOGEN INC.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SHANGHAI MIRACOGEN INC.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K38/1808, A61K39/001104, A61K47/68031, A61K47/6811
More from SHANGHAI MIRACOGEN INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10792370?
US 10792370 (Antibody-drug conjugate) is held by SHANGHAI MIRACOGEN INC.. Status: granted. Granted Oct 6, 2020. Expires Oct 1, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10792370?
SHANGHAI MIRACOGEN INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10792370 expire?
Our index shows an expiration date of Oct 1, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.